Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

NCT01692262 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castrate-Resistant Prostate Cancer (mCRPC),
Efficacy,
Safety and Tolerability,
Pharmacokinetics,
Pharmacodynamics,
Tumour Response.

Interventions

DRUG: Intermittent dosing of AZD5363
DRUG: Intermittent dosing of AZD5363
DRUG: Intermittent dosing of AZD5363

Sponsor

AstraZeneca